
|Articles|February 10, 2022
Daily Medication Pearl: Diroximel Fumarate (Vumerity)
Author(s)Saro Arakelians, PharmD
Diroximel fumarate (Vumerity) is indicated for the treatment of relapsing forms of multiple sclerosis.
Advertisement
Medication Pearl of the Day: Diroximel fumarate (Vumerity)
Indication: Diroximel fumarate (Vumerity)is indicated for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Insight:
- Dosing: Starting dose 231 mg twice a day, orally, for 7 days. Maintenance dose after 7 days 462 mg administered as two 231 mg capsules twice a day, orally.
- Dosage forms: Delayed-release capsules 231 mg.
- Adverse events: Most common adverse reactions for dimethyl fumarate were flushing, abdominal pain, diarrhea, and nausea.
- Mechanism of action: MMF, the active metabolite of diroximel fumarate, has been shown to activate the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathways in vitro and in vivo in animals and humans. The Nrf2 pathway is involved in the cellular response to oxidative stress. MMF has been identified as a nicotinic acid receptor agonist in vitro.
- Manufacturer: Biogen
Sources:
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
The Peptide Reclassification Everyone's Talking About: A Pharmacist's Take on What RFK Jr's Announcement Actually Means
2
What Pharmacists Need to Know About Retatrutide's TRIUMPH-1 Phase 3 Results
3
Subcutaneous Isatuximab On-Body Injector Shows High Reliability, Favorable Safety Across Multiple Myeloma Trials
4
Collaboration, Innovation, Stewardship, and the Future of Infectious Diseases Pharmacotherapy and Practice
5




























































































































